[1]徐俊波 黄刚 蔡琳 余秀琼 刘汉雄.肿瘤心血管病学的循证临床实践[J].心血管病学进展,2020,(5):468-471.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.007]
　XU Junbo,HUANG Gang,CAI Lin,et al.Evidence-based Clinical Management in Cardio-Oncology[J].Advances in Cardiovascular Diseases,2020,(5):468-471.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.007]
点击复制

肿瘤心血管病学的循证临床实践()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年5期
页码:
468-471
栏目:
出版日期:
2020-05-25

文章信息/Info

Title:
Evidence-based Clinical Management in Cardio-Oncology
作者:
徐俊波 黄刚 蔡琳 余秀琼 刘汉雄
（成都市心血管病研究所 成都市第三人民医院心血管内科 西南交通大学附属医院,重庆医科大学附属成都第二医院,四川 成都 610031)
Author(s):
XU Junbo;  HUANG Gang;  CAI Lin;  YU Xiuqiong;  LIU Hanxiong
(Department of Cardiology,The Third Peoples Hospital of Chengdu,Cardiovascular Disease Research Institute of Chengdu,Clinical College of Southwest Jiaotong University,The Second Affiliated Chengdu Clinical College of Chongqing Medical University,Chengdu 610031,Sichuan,China)
关键词:
肿瘤心血管病学; 抗肿瘤治疗; 心血管毒性
Keywords:
Cardio-oncology; Anti-cancer therapy; Cardiotoxicity
DOI:
10.16806/j.cnki.issn.1004-3934.2020.05.007
摘要:
肿瘤疾病和心血管疾病均是目前全球的重大疾病负担和挑战。预期寿命得到延长的肿瘤患者，罹患抗肿瘤治疗相关的心血管疾病的概率明显增加,作为多学科整合的肿瘤心血管病学方兴未艾。现着重介绍当前肿瘤心血管病学的临床管理实践策略，为广大临床医师提供参考。
Abstract:
Cancer and cardiovascular disease are currently important disease-related burdens and challenges worldwide. Cancer therapeutics-related cardiovascular diseases become more commonly in cancer patients with longer expected life time than before. In this background, cardio-oncology is emerging as a multi-discipline in past decades. Here, we introduce the general management in clinical practice of cardio-oncology in this article, which may be helpful for physicians in daily practice.

参考文献/References:

[1] Ferlay J,?Soerjomataram I,?Dikshit R,?et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 [J].Int J?Cancer,2015,136(5):E359-E386.

[2] Zhou M,Wang H,Zeng X,et al. Mortality,morbidity,and risk factors in?China?and its provinces,1990-2017:a systematic analysis for the Global?Burden?of?Disease?Study 2017[J]. Lancet,2019,394(10204):1145-1158.

[3] Huang G,Yeung CY,Lee KK,et al. Androgen deprivation therapy and cardiovascular risk in Chinese patients with nonmetastatic carcinoma of prostate[J]. J Oncol,2014,2014:529468.

[4] Tsch?pe C,Kherad B,Spillmann F,et al. Kardiovaskula?res Risiko unter Androgendeprivationstherapie zur Behandlung des hormonab-ha?ngigen Prostatakarzinoms:Unterschiede zwischen GnRH-Antagonisten gegenu?ber GnRH-Agonisten [J]. Herz,2016,41(8):697-705.

[5] 王阿曼,夏云龙.大数据时代肿瘤心脏病学的机遇和挑战[J].心血管病学进展,2018,39(2):135-138.

[6] Zhang Y,Liu Y,Xia Y. Dedicated to cardio-oncology[J].Eur Heart J,2020,41(8):907-909.

[7] 安涛,赵雪梅,张宇辉. 靶向药物治疗所致心功能异常的防治[J].中国实用内科杂志,2018,38(7):596-598.

[8] Hohmann C, Baldus S, Pfister R. Krebserkrankungen heilen und das Herz schu?tzen: Herausforderungen der Kardioonkologie im Zeitalter moderner Tumortherapien [J]. Herz,2019,44(2):175-188.

[9] Meijers WC, de Boer RA. Common risk factors for heart failure and cancer[J].Cardiovasc Res,2019,115(5):844-853.

[10] Zamorano JL, Lancellotti P, Rodriguez Mu?oz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:The Task Force for?cancer treatments?and?cardiovascular?toxicity?of the European Society of Cardiology(ESC)[J]. Eur Heart J,2016,37(36):2768-2801.

[11] Pondé NF,Lambertini M,de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity[J].ESMO Open,2016,1(4):e000073.

[12] Rini BI, Cohen DP, Lu DR,et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib[J].J Natl Cancer Inst,2011,103(9):763-773.

[13] Escudier M,Cautela J,Malissen N,et al. Clinical features,management,and outcomes of immune checkpoint inhibitor-related cardiotoxicity[J]. Circulation,2017,136(21):2085-2087.

[14] Barber M,Nguyen LS,Wassermann J,et al.Cardiac arrhythmia considerations of hormone cancer therapies[J]. Cardiovasc Res,2019,115(5):878-894.

[15] Mahmood SS, Nohria A. Cardiovascular complications of cranial and neck radiation[J]. Curr Treat Options Cardiovasc Med,2016,18(7):45.

[16] Sharabi Y,Dendi R,Holmes C,et al. Baroreflex failure as a late sequela of neck irradiation[J].Hypertension,2003,42(1):110-116.

[17] Lau WY,Chow CK.Radiation-induced petrous internal carotid artery aneurysm[J].Ann Otol Rhinol Laryngol,2005,114(12):939-940.

[18] Cheng SW,Wu LL,Ting AC,et al. Irradiation-induced extracranial carotid stenosis in patients with head and neck malignancies[J]. Am J Surg,1999,178(4):323-328

[19] Thavendiranathan P,Grant AD,Negishi T,et al.Reproducibility echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes:application to patients undergoing cancer chemotherapy[J]. J Am Coll Cardiol,2013,61(1):77-84.

[20] McDonald JP,MacNamara JP,Zaha VG. Challenges in implementing optimal echocardiographic screening in cardio-oncology[J].Curr Treat Options Cardiovasc Med,2019,21(8):39.

[21]Balanescu DV,Monlezun DJ,Donisan T,et al. A cancer paradox: machine-learning backed propensity-score analysis of coronary angiography findings in cardio-oncology[J].J Invasive Cardiol,2019,31(1):21-26.

[22] Bhatia N,Santos M,Jones LW,et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer:ABCDE steps to reduce cardiovascular disease in patients with prostate cancer[J].Circulation,2016,133(5):537-541.

[23] Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies [J].N Engl J Med,2016,375(15):1457-1467.

相似文献/References:

[1]蒋弼瀛 黄佳宇 陈文佳.肿瘤相关血压的血压管理的研究进展[J].心血管病学进展,2024,(1):52.[doi:10.16806/j.cnki.issn.1004-3934.202.01.014]
　JIANG Biying,HUANG Jiayu,CHEN Wenjia.Blood Pressure Management of Tumor-Associated Hypertension[J].Advances in Cardiovascular Diseases,2024,(5):52.[doi:10.16806/j.cnki.issn.1004-3934.202.01.014]

备注/Memo

备注/Memo:
———————————————————— 基金项目：成都市科技局项目(11PPYB034SF-289) 收稿日期：2019-11-25 表1 常见的抗肿瘤药物及心血管系统损伤心血管损伤药物种类
更新日期/Last Update: 2020-08-12